VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

ALVAC-AI-H5(H5N1) C-KCE (vBAC-C-KCE) rDEV-us78HA rFPV-AI-H5A-IL6 rNDV-H5 ( HPAI H5N1 challenge in mule ducks) vFP89-H5
Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004730
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: Fowlpox (FP)-vectored avian influenza (FP-AI) (Bublot et al., 2010).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004812
  • Type: Other
  • Status: Licensed
  • Host Species for Licensed Use: Baboon
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004658
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: rDEV-ul41HA and rDEV-us78HA, in which the hemagglutinin (HA) gene of the H5N1 virus A/duck/Anhui/1/06 was inserted and stably maintained within the ul41 gene or between the us7 and us8 genes of the DEV genome (Liu et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004743
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: Recombinant fowlpox virus (rFPV-AIH5AIL6) coexpressing the haemagglutinin (HA) gene of the H5N1 subtype of the avian influenza virus (AIV) and chicken interleukin 6 gene (Qian et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004682
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: Newcastle disease virus (NDV) vector expressing an H5N1 hemagglutinin (rNDV-H5) (Ferreira et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004620
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Preparation: Recombinant vaccine (vNDV-H5) encoding an optimized synthetic haemagglutinin gene from a clade 2.2.1 H5N1 highly pathogenic (HP) avian influenza virus (AIV), either as a single administration or as a boost following a prime inoculation with a fowlpox vectored vaccine (vFP89) encoding a different H5 HP haemagglutinin from an Irish H5N8 strain (Niqueux et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response Host Response Host Response Host Response Host Response

Ducks Response

  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Immunogenicity induced by the three poxvirus vectors was comparable, and the FP vector was selected for the other studies. As published previously, there was a strong dose effect of the FP-AI priming on the hemagglutination inhibition (HI) titers induced after the boost with an inactivated vaccine. In contrast, the two tested adjuvants did not significantly increase the activity of FP-AI priming. The heterologous prime-boost regimen given to both Muscovy and Pekin ducklings at 1 and 14 or 21 days of age, respectively, was shown to be at least as immunogenic as two administrations of inactivated vaccines given at 2 and 5 wk of age (Bublot et al., 2010).

Ducks Response

  • Vaccination Protocol: The attenuated DEV C-KCE vaccine strain, obtained from the China Institute of Veterinary Drugs Control, was propagated and titrated in primary chicken embryo fibroblasts (CEF) propagated in Eagle’s minimal essential medium (EMEM, Biochrom), which was supplemented with 100 μg/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FBS) at 37 °C under a 5% CO2 atmosphere. A virulent DEV strain (HB/10) isolated from Hubei Province in the central part of China was propagated and titrated in duck embryo fibroblasts (DEF). AIV H5N1 A/duck/Hubei/xn/2007 (H5N1) (XN/07) (clade 2.3.2) (GenBank accession number of HA: AHI43271.1) and A/duck/Hubei/HangMei01/2006 (HM/06) (clade 2.3.4) (GenBank accession number of HA: ACF16400.1) were propagated in the allantoic cavities of 10-day-old specific-pathogen-free (SPF) embryonated chicken eggs and stored at −80 °C. (Zou et al., 2015)
  • Immune Response: Ducks immunized with C-KCE-HA induced both the cross-reactive antibodies and T cell response against H5 (Zou et al., 2015).
  • Efficacy: C-KCE-HA-immunized ducks provided rapid and long-lasting protection against homologous and heterologous HPAIV H5N1 and DEV clinical signs, death, and primary viral replication (Zou et al., 2015).
  • Host IFNG from Macaca nemestrina response
    • Description: Vaccination with C-KCE induced upregulation of IFN-G in ducks T cells (Zou et al., 2015).
    • Detailed Gene Information: Click Here.

Ducks Response

  • Vaccination Protocol: Ducks were inoculated intramuscularly with 0.1 ml of serum-free minimum essential medium diluted virus (Liu et al., 2011).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: The ducks were challenged with lethal DEV or H5N1 AIV at different time points postvaccination (p.v.) (Liu et al., 2011).
  • Efficacy: All of the ducks in the groups inoculated with DEV and rDEV-us78HA remained healthy during the 2-week observation period. These results indicate that the recombinant viruses bearing the H5 HA gene insertion have immunogenicity similar to that of the DEV vaccine strain and induced protective immunity against lethal DEV challenge in as little as 3 days post vaccination (Liu et al., 2011).

Ducks Response

  • Vaccination Protocol: The ducks were immunized subcutaneously with rFPV-SYHA, rFPV-AIH5AIL6, rFPV-IL6 and wt-FPV, respectively, at a titre of 105 PFU in a 0.2-ml inoculum (Qian et al., 2012).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Each duck was challenged with 0.2 ml of 105.75 EID50 of H5 AIV A/mallard/Huadong/SY/2005 by nose/eye drop (Qian et al., 2012).
  • Efficacy: These animal studies demonstrated that rFPV-AIH5AIL6 induced a higher anti-AIV HI antibody response, an enhanced lymphocyte proliferation response, an elevated immune protection, and a reduction in virus shedding compared to a recombinant fowlpox virus expressing the HA gene alone (rFPV-SYHA) (Qian et al., 2012).

Ducks Response

  • Vaccination Protocol: The ducks were vaccinated with NDV-H5 (Ferreira et al., 2012).
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Our results showed the rNDV-H5 vaccine elicits satisfactory humoral and cellular responses in 11-day-old ducks correlating with a complete clinical and virological protection against the H5N1 strain (Ferreira et al., 2012).

Ducks Response

  • Vaccination Protocol: Ducks were divided into two groups and one group had vFP89 vaccine was inoculated subcutaneously in the back of the neck, at 104.5 TCID50/0.2 ml dose. The second group hadRe-5 vaccine was injected subcutaneously as a single 0.5 ml dose (Niqueux et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: HPAIV challenge was done in a large BSL3 isolator at 43, 65 or 86 days of age respectively. All vaccinated or control ducks were inoculated by oculo-nasal instillation with 100 μl of a virus dilution containing 106 EID50 of HPAIV H5N1 A/mute swan/France/06299/06 strain, prepared in phosphate-buffered saline as previously described (Niqueux et al., 2013).
  • Efficacy: Only the prime-boost vaccination (vFP89+vNDV-H5) was still fully protecting Muscovy ducks against disease and mortality at 12 weeks of age. Reduction of oropharyngeal shedding levels was also constantly observed from the onset of the follow-up at 2.5 or three days post-infection in vaccinated ducks compared to unvaccinated controls, and was significantly more important for vFP89+vNDV-H5 vaccination than for vNDV-H5 alone (Niqueux et al., 2013).
References References References References References References
Bublot et al., 2010: Bublot M, Richard-Mazet A, Chanavat-Bizzini S, Le Gros FX, Duboeuf M, Stoll A, Palfi V, Niqueux E, Guionie O, Dren N. Immunogenicity of poxvirus vector avian influenza vaccines in Muscovy and Pekin ducks. Avian diseases. 2010; 54(1 Suppl); 232-238. [PubMed: 20521637].
Zou et al., 2015: Zou Z, Hu Y, Liu Z, Zhong W, Cao H, Chen H, Jin M. Efficient strategy for constructing duck enteritis virus-based live attenuated vaccine against homologous and heterologous H5N1 avian influenza virus and duck enteritis virus infection. Veterinary research. 2015; 46(1); 42. [PubMed: 25889564].
Liu et al., 2011: Liu J, Chen P, Jiang Y, Wu L, Zeng X, Tian G, Ge J, Kawaoka Y, Bu Z, Chen H. A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. Journal of virology. 2011; 85(21); 10989-10998. [PubMed: 21865383].
Qian et al., 2012: Qian C, Chen S, Ding P, Chai M, Xu C, Gan J, Peng D, Liu X. The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks. Vaccine. 2012; 30(44); 6279-6286. [PubMed: 22902682].
Ferreira et al., 2012: Ferreira HL, Pirlot JF, Reynard F, van den Berg T, Bublot M, Lambrecht B. Immune responses and protection against H5N1 highly pathogenic avian influenza virus induced by the Newcastle disease virus H5 vaccine in ducks. Avian diseases. 2012; 56(4 Suppl); 940-948. [PubMed: 23402116].
Niqueux et al., 2013: Niqueux E, Guionie O, Amelot M, Jestin V. Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus. Vaccine. 2013; 31(38); 4121-4128. [PubMed: 23845804].